Details of Drug

Details of Drug

 Drug General Information (ID: D0086)
  Drug Name
Anastrozole
  Drug Type Small molecule
  Drug Synonymous
Anastrazole; Anastrole; Anastrozol; Arimidex; Asiolex; Astra brand of anastrozole; AstraZeneca brand of anastrozole; Zeneca brand of anastrozole; ZD 1033; ZD1033; Zeneca ZD 1033; Arimidex (TN); Arimidex (Zeneca); Arimidex, Anastrozole; ZD-1033; Anastrozole [USAN:INN:BAN]; Anastrozole (JAN/USAN/INN); Alpha,alpha,alpha',alpha'-tetramethyl-5(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile; Alpha,alpha,alpha',alpha'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile; 1,3-benzenediacetonitrile, a, a,a', a'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl); 2,2'-(5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile); 2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropanenitrile); 2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)benzene-1,3-diyl]bis(2-methylpropanenitrile); 2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile
    Click to Show/Hide
  Disease Class 2C60-2C6Y: Breast cancer
  Therapeutic Class Antineoplastics
  Structure Could Not Find 2D Structure
3D Structure 2D Structure
  Formula C17H19N5
  InChI 1S/C17H19N5/c1-16(2,9-18)14-5-13(8-22-12-20-11-21-22)6-15(7-14)17(3,4)10-19/h5-7,11-12H,8H2,1-4H3
  InChIKey YBBLVLTVTVSKRW-UHFFFAOYSA-N
  Canonical SMILES CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N
  External Link
Pubchem ID 2187
CAS Number 120511-73-1
CHEBI ID 2704
TTD ID D0W0BF
INTEDE ID DR0113
VARIDT ID DR00464

Drug-Drug Interaction Network
  Sunburst Graph
AM004  Affected intra/extra-hepatic metabolism
AM006  Pharmacodynamic additive effects
AM007  Pharmacodynamic antagonistic effects
BM017  CYP450 enzyme inhibition
BM047  Additive thrombogenic effects
BM107  Attenuated pharmacological effects (Unspecific)
  Relation Graph
 Full list of drugs interacting with Anastrozole
      Affected intra/extra-hepatic metabolism
   CYP450 enzyme inhibition Drug Num:  2
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D0699
 
Fostamatinib
 
C23H26FN6O9P
 
11671467 
Moderate    Inter Info   
[20]
D1660
 
Tucatinib
 
C26H24N8O2
 
51039094 
Moderate    Inter Info   
[21]
      Pharmacodynamic additive effects
   Additive thrombogenic effects Drug Num:  1
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D1569
 
Thalidomide
 
C13H10N2O4
 
5426 
Major    Inter Info   
[1], [2], [3], [4], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16]
      Pharmacodynamic antagonistic effects
   Attenuated pharmacological effects (Unspecific) Drug Num:  14
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D0605
 
Esterified estrogens
 
NA
 
NA
Moderate    Inter Info   
[17], [18], [19]
D0610
 
Estrone sulfate
 
C18H22O5S
 
3001028 
Moderate    Inter Info   
[17], [18], [19]
D0611
 
Estrone sulfate (topical)
 
C18H22O5S
 
3001028 
Moderate    Inter Info   
[17], [18], [19]
D1011
 
Mestranol
 
C21H26O2
 
6291 
Moderate    Inter Info   
[17], [18], [19]
D1370
 
Quinestrol
 
C25H32O2
 
9046 
Moderate    Inter Info   
[17], [18], [19]
D0387
 
Conjugated estrogens
 
C18H21NaO5S
 
45357473 
Moderate    Inter Info   
[17], [18], [19]
D0388
 
Conjugated estrogens (topical)
 
C18H21NaO5S
 
45357473 
Moderate    Inter Info   
[17], [18], [19]
D0484
 
Dienestrol (topical)
 
C18H18O2
 
667476 
Moderate    Inter Info   
[17], [18], [19]
D0487
 
Diethylstilbestrol
 
C18H20O2
 
448537 
Moderate    Inter Info   
[17], [18], [19]
D0606
 
Estradiol
 
C18H24O2
 
5757 
Moderate    Inter Info   
[17], [18], [19]
D0607
 
Estradiol (topical)
 
C18H24O2
 
5757 
Moderate    Inter Info   
[17], [18], [19]
D0608
 
Estramustine
 
C23H31Cl2NO3
 
259331 
Moderate    Inter Info   
[17], [18], [19]
D0609
 
Estrone
 
C18H22O2
 
5870 
Moderate    Inter Info   
[17], [18], [19]
D0619
 
Ethinylestradiol
 
C20H24O2
 
5991 
Moderate    Inter Info   
[17], [18], [19]
References
1 Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
2 Bennett CL, Schumock GT, Desai AA, et al "Thalidomide-associated deep vein thrombosis and pulmonary embolism." Am J Med 113 (2002): 603-6. [PMID: 12459408]
3 Cavo M, Zamagni E, Cellini C, et al. "Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy." Blood 100 (2002): 2272-3. [PMID: 12229885]
4 Escudier B, Lassau N, Leborgne S, Angevin E, Laplanche A "Thalidomide and venous thrombosis." Ann Intern Med 136 (2002): 711. [PMID: 11992318]
5 Figg WD, Arlen P, Gulley J, et al. "A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer." Semin Oncol 28(4 Suppl 15) (2001): 62-6. [PMID: 11685731]
6 Fine HA, Wen PY, Maher EA, et al. "Phase II Trial of Thalidomide and Carmustine for Patients With Recurrent High-Grade Gliomas." J Clin Oncol 21 (2003): 2299-304. [PMID: 12805330]
7 Lee CK, Barlogie B, Munshi N, et al "DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma." J Clin Oncol 21 (2003): 2732-9. [PMID: 12860952]
8 Osman K, Comenzo R, Rajkumar SV "Deep venous thrombosis and thalidomide therapy for multiple myeloma." N Engl J Med 344 (2001): 1951-2. [PMID: 11419443]
9 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
10 Rajkumar SV, Hayman S, Gertz MA, et al. "Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma." J Clin Oncol 20 (2002): 4319-23. [PMID: 12409330]
11 Urbauer E, Kaufmann H, Nosslinger T, Raderer M, Drach J "Thromboembolic events during treatment with thalidomide." Blood 99 (2002): 4247-8. [PMID: 12043695]
12 Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R "Thalidomide alone or with dexamethasone for previously untreated multiple myeloma." J Clin Oncol 21 (2003): 16-9. [PMID: 12506164]
13 Zangari M, Anaissie E, Barlogie B, et al "Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy." Blood 98 (2001): 1614-5. [PMID: 11520815]
14 Zangari M, Barlogie B, Anaissie E, et al "Deep vein thrombosis in patients with mutiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation." Br J Haematol 126 (2004): 715-21. [PMID: 15327525]
15 Zangari M, Siegel E, Barlogie B, et al "Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy." Blood 100 (2002): 1168-71. [PMID: 12149193]
16 Desai AA, Vogelzang NJ, Rini BI, Ansari R, Krauss S, Stadler WM "A high rate of venous thromboembolism in a multi-institutional Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma." Cancer 95 (2002): 1629-36. [PMID: 12365009]
17 Product Information. Aromasin (exemestane) Pharmacia &amp Upjohn, Kalamazoo, MI.
18 Product Information. Femara (letrozole). Novartis Pharmaceuticals, East Hanover, NJ.
19 Product Information. Arimidex (anastrozole). Zeneca Pharmaceuticals, Wilmington, DE.
20 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
21 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.